EGFR and melanoma: Indeed, lapatinib, a clinical ERBB2 and EGFR inhibitor, effectively inhibited the ERBB3/ERBB2 pathway and importantly, delayed melanoma tumor growth in both mutated and wild type BRAF cells [3].